Park Place Capital Corp Sells 3,222 Shares of Sanofi (NASDAQ:SNY)

Park Place Capital Corp reduced its stake in Sanofi (NASDAQ:SNY) by 34.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 6,241 shares of the company’s stock after selling 3,222 shares during the quarter. Park Place Capital Corp’s holdings in Sanofi were worth $301,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in SNY. Jennison Associates LLC grew its holdings in shares of Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after buying an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company’s stock valued at $36,869,000 after purchasing an additional 331,445 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Trading Down 0.3 %

NASDAQ:SNY opened at $51.51 on Thursday. The company has a market cap of $130.72 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a 50 day simple moving average of $48.53 and a two-hundred day simple moving average of $52.16. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 earnings per share. Research analysts forecast that Sanofi will post 3.82 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.